Key result
Diabetes mellitus is a strong independent risk factor for atrial fibrillation, and current evidence suggests that SGLT2 inhibitors may offer advantages over other glucose-lowering therapies in preventing its development.
Why the study?
Diabetes mellitus is a strong independent risk factor for atrial fibrillation, and their increasingly common combination creates a high risk of complications and poor outcomes.
SGLT2 inhibitors appear to offer advantages in preventing atrial fibrillation in patients with diabetes mellitus compared to other glucose-lowering therapies.
DM strongly predicts AF; review leaves open optimal glycemic targets for prevention.
Diabetes mellitus (DM) is one of the strongest independent risk factors for the development of atrial fibrillation (AF). Their combination is increasingly common, creating a high risk of complications and poor outcome in patients. A search and analysis of 8907 literature sources from the Scopus, Web of Science, PubMed/MedLine, The CochraneLibrary databases was carried out for the keywords "diabetes mellitus", "atrial fibrillation", "glycemic control", "hypoglycemic therapy". The review presents current ideas about the mechanisms underlying the development of AF in DM, as well as the effect of certain classes of hypoglycemic and other drugs on the risk of AF, some features of the treatment of AF in combination with DM.
No takes yet. Share an insight, caveat, or question.
Канорский et al. (2023) conducted a review in Diabetes mellitus and atrial fibrillation. Hypoglycemic therapy (including SGLT2 inhibitors) vs. Other glucose-lowering therapies or placebo was evaluated. Diabetes mellitus is a strong independent risk factor for atrial fibrillation, and current evidence suggests that SGLT2 inhibitors may offer advantages over other glucose-lowering therapies in preventing its development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: